M
Makhdum Ahmed
Researcher at University of Texas MD Anderson Cancer Center
Publications - 46
Citations - 2447
Makhdum Ahmed is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Mantle cell lymphoma & Ibrutinib. The author has an hindex of 15, co-authored 46 publications receiving 1631 citations. Previous affiliations of Makhdum Ahmed include University of Texas Health Science Center at Houston & University of Texas System.
Papers
More filters
Journal ArticleDOI
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
A. Danielle Iuliano,Katherine Roguski,Howard H. Chang,David Muscatello,Rakhee Palekar,Stefano Tempia,Cheryl Cohen,Jon Michael Gran,Jon Michael Gran,Dena L. Schanzer,Benjamin J. Cowling,Peng Wu,Jan Kynčl,Li Wei Ang,Minah Park,Monika Redlberger-Fritz,Hongjie Yu,Laura Espenhain,Anand Krishnan,Gideon O. Emukule,Liselotte van Asten,Susana Silva,Suchunya Aungkulanon,Udo Buchholz,Marc-Alain Widdowson,Joseph S. Bresee,Eduardo Azziz-Baumgartner,Po-Yung Cheng,Fatimah S. Dawood,Ivo M. Foppa,Sonja J. Olsen,Michael Haber,Caprichia Jeffers,C. Raina MacIntyre,Anthony T. Newall,James G. Wood,Michael Kundi,Therese Popow-Kraupp,Makhdum Ahmed,Mahmudur Rahman,Fatima Marinho,C Viviana Sotomayor Proschle,Natalia Vergara Mallegas,Feng Luzhao,Li Sa,Juliana Barbosa-Ramírez,Diana Malo Sanchez,Leandra Abarca Gomez,Xiomara Badilla Vargas,aBetsy Acosta Herrera,María Josefa Llanés,Thea Kølsen Fischer,Tyra Grove Krause,Kåre Mølbak,Jens Nielsen,Ramona Trebbien,Alfredo Bruno,Jenny Ojeda,Hector Ramos,Matthias an der Heiden,Leticia del Carmen Castillo Signor,Carlos Enrique Serrano,Rohit Bhardwaj,Mandeep S. Chadha,Venkatesh Vinayak Narayan,Soewarta Kosen,Michal Bromberg,Aharona Glatman-Freedman,Zalman Kaufman,Yuzo Arima,Kazunori Oishi,Sandra S. Chaves,Bryan O. Nyawanda,Reem Abdullah Al-Jarallah,Pablo A Kuri-Morales,Cuitláhuac Ruiz Matus,Maria Eugenia Jimenez Corona,Alexander Burmaa,Oyungerel Darmaa,Majdouline Obtel,Imad Cherkaoui,Cees C van den Wijngaard,Wim van der Hoek,Michael G Baker,Don Bandaranayake,Ange Bissielo,Sue Huang,Liza Lopez,Claire Newbern,Elmira Flem,Gry M Grøneng,Siri Hauge,Federico G de Cosío,Yadira De Molto,Lourdes Moreno Castillo,María Agueda Cabello,Marta Von Horoch,José L. Medina Osis,Ausenda Machado,Baltazar Nunes,Ana Paula Rodrigues,Emanuel Rodrigues,Cristian Calomfirescu,Emilia Lupulescu,Rodica Popescu,Odette Popovici,Dragan Bogdanovic,Marina Kostic,Konstansa Lazarevic,Zoran Milosevic,Branislav Tiodorovic,Mark I-Cheng Chen,Jeffery Cutter,Vernon J. Lee,Raymond T. P. Lin,Stefan Ma,Adam L. Cohen,Florette K. Treurnicht,Woo Joo Kim,Concha Delgado-Sanz,Salvador de mateo Ontañón,Amparo Larrauri,Inmaculada León,Fernando Vallejo,Rita Born,Christoph Junker,Daniel Koch,Jen-Hsiang Chuang,Wan-Ting Huang,Hung-Wei Kuo,Yi-Chen Tsai,Kanitta Bundhamcharoen,Malinee Chittaganpitch,Helen K. Green,Richard Pebody,Natalia Goñi,Hector Chiparelli,Lynnette Brammer,Desiree Mustaquim +138 more
TL;DR: These global influenza-associated respiratory mortality estimates are higher than previously reported, suggesting that previous estimates might have underestimated disease burden.
Journal ArticleDOI
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
Liang Zhang,Yixin Yao,Shaojun Zhang,Yang Liu,Hui Guo,Makhdum Ahmed,Taylor Bell,Hui Zhang,Guangchun Han,Elizabeth Lorence,Maria Badillo,Shouhao Zhou,Yuting Sun,M. Emilia Di Francesco,Ningping Feng,Randy S. Haun,Renny S. Lan,Samuel G. Mackintosh,Xizeng Mao,Xingzhi Song,Jianhua Zhang,Lan V. Pham,Philip L. Lorenzi,Joseph R. Marszalek,Timothy P. Heffernan,Giulio Draetta,Philip Jones,Andrew Futreal,Krystle Nomie,Linghua Wang,Michael Wang +30 more
TL;DR: Genomic analyses of clinical specimens show that metabolic reprogramming toward oxidative phosphorylation (OXPHOS) and glutaminolysis is associated with therapeutic resistance to the Bruton’s tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma, suggesting that targeting metabolic pathways to subvert therapeutic resistance is a clinically viable approach to treat highly refractory malignancies.
Journal ArticleDOI
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Preetesh Jain,Rashmi Kanagal-Shamanna,Shaojun Zhang,Makhdum Ahmed,Ahmad Ghorab,Liang Zhang,Chi Young Ok,Shaoying Li,Frederick B. Hagemeister,Dongfeng Zeng,Tiejun Gong,Wendy Chen,Maria Badillo,Krystle Nomie,Luis Fayad,L. J. Medeiros,Sattva S. Neelapu,Nathan Fowler,Jorge E. Romaguera,Richard E. Champlin,Linghua Wang,Michael L. Wang +21 more
TL;DR: Demonstration of TP53 and NSD2 mutations in patients who developed blastoid transformation and ATM and TP53 mutations in Patients who progressed, opens the door for future investigations in ibrutinib‐refractory MCL.
Journal ArticleDOI
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
TL;DR: Targeted agents such as ibrutinib, an inhibitor of Bruton’s tyrosine kinase, which has been approved only in the relapsed setting, can be used to treat patients with relapsed or refractory mantle cell lymphoma.
Journal ArticleDOI
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Liang Zhang,Krystle Nomie,Hui Zhang,Taylor Bell,Lan V. Pham,Sabah Kadri,Jeremy P. Segal,Shaoying Li,Shouhao Zhou,David Santos,Shawana Richard,Shruti Sharma,Wendy Chen,Onyekachukwu Oriabure,Yang Liu,Shengjian Huang,Huifang Guo,Zhihong Chen,Wenjing Tao,Carrie J Li,Jack Wang,Bingliang Fang,J. Wang,Lei Li,Maria Badillo,Makhdum Ahmed,Selvi Thirumurthi,Steven Y. Huang,Yiping Shao,Laura T Lam,Qing Yi,Lynn Y. Wang,Michael Wang +32 more
TL;DR: The results demonstrate that the B-cell lymphoma PDX model is an effective system to predict and personalize therapies and address therapeutic resistance in B- cell lymphoma patients.